[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483520":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":20,"responsibleParty":38,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Primary brain tumour patients receiving RT",null,"Primary brain tumor patients are screened at time of consultation for this observational study, and the study population is diverse across sex\u002Fgender, and racial\u002Fethnic groups.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Sheila Medina","CONTACT","858-822-6575","s4medina@health.ucsd.edu",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":10},"Jona Hattangadi-Gluth, MD",[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Moores Cancer Center","RECRUITING","San Diego","California","92037","United States",{"type":29,"coordinates":30},"Point",[31,32],-117.16472,32.71571,{"lat":32,"lon":31},[35,37],{"name":36,"role":15,"phone":16,"phoneExt":10,"email":17},"Lara J Rose",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Jona Hattangadi-Gluth","Professor","100483520",false,"NCT05576103","Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients","Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging Outcomes in Primary Brain Tumor Patients Receiving Brain Radiotherapy","Inclusion Criteria:\n\n1. Patients 18 years or older\n2. Karnofsky performance status (KPS) ≥70\n3. Life expectancy of ≥1 year\n4. Primary brain tumor patients who will receive fractionated partial brain RT\n5. Able to complete neurocognitive assessments\n\nExclusion Criteria:\n\n1. Inability to undergo MRI with contrast\n2. Prior brain RT","ALL","18 Years","99 Years",{"count":52,"type":53},300,"ESTIMATED","OBSERVATIONAL","In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.",[57,58,59,60],"Primary Brain Tumor","Glioma","Meningioma","Schwannoma","2026-06-09",{"date":63,"type":64},"2026-06-10","ACTUAL",{"date":66,"type":64},"2015-01",{"date":68,"type":53},"2030-12",{"name":40,"class":6},1]